Mark Pykett
Director/Board Member at PHARMING GROUP N.V.
Net worth: 114 989 $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Matthew Klein | M | 52 | 5 years | |
| Philippe Guedat | M | - |
Inflectis Bioscience SAS
 Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | 11 years |
| Sijmen de Vries | M | 65 | 16 years | |
| Pierre Miniou | M | - |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | 11 years |
| Dennis F. Steadman | M | 70 |
Exubrion Therapeutics , Inc.
 Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | - |
| Leonard Kruimer | M | 66 | 3 years | |
| Emma Reeve | F | 63 | 6 years | |
| Verena Schöwel-Wolf | M | - |
MyoPax GmbH
 MyoPax GmbH BiotechnologyHealth Technology MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders. | 2 years |
| Diane Seimetz | M | 53 |
MyoPax GmbH
MyoPax GmbH BiotechnologyHealth Technology MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders. | 2 years |
| Mireille Sanders | F | 56 | 5 years | |
| Stephanie Okey | F | 64 | 6 years | |
| Michael Levitan | M | 66 | - | |
| Ruud van Outersterp | M | 60 | 4 years | |
| Deborah Jorn | F | 66 | 5 years | |
| Simone Spuler | M | - |
MyoPax GmbH
MyoPax GmbH BiotechnologyHealth Technology MyoPax GmbH is a biotech start-up located in Germany and Denmark that focuses on innovative regenerative therapies for muscle disorders. The German company was spun out of the Charité Universitätsmedizin and the Max Delbrück Center in the Helmholtz Association and joined the BioInnovation Institute in Copenhagen with pre-seed funding. MyoPax leverages its proprietary muscle stem cell technology and cutting-edge gene editing technologies to transform the treatment landscape and improve the quality of life for patients affected by muscle disorders. | 2 years |
| Jeanine Clemente | F | - | 5 years | |
| Anurag Relan | M | 52 | - | |
| Stephen Toor | M | 52 | 4 years | |
| Richard Peters | M | 61 | 1 years | |
| Jabine T. M. van der Meijs | M | 58 | 3 years | |
| Michael McCall | M | 85 |
Cytomatrix
 Cytomatrix Miscellaneous Commercial ServicesCommercial Services Part of Cordlife Group Ltd., Cytomatrix is a company that researches, develops, and commercializes novel cell growth systems for hematopoietic (blood) stem cells. The company is based in Woburn, MA. The company was founded by Mark Jerome Pykett. Cytomatrix was acquired by Cordlife Group Ltd. on April 30, 2003 for $11 million. | 25 years |
| Barbara Yanni | F | 69 | 4 years | |
| Jerome Gueret | M | - |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | - |
| Robin Readnour | M | 60 |
Exubrion Therapeutics , Inc.
Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | - |
| Steven Baert | M | 50 | 3 years | |
| Jeroen Wakkerman | M | 55 | 4 years | |
| Nigel Raymond Stevenson | M | - |
Exubrion Therapeutics , Inc.
Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | 5 years |
| Philippe Jaffré | M | - |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | - |
| Taro Inaba | M | 56 |
Inflectis Bioscience SAS
Inflectis Bioscience SAS BiotechnologyHealth Technology Inflectis Bioscience SAS develops therapeutics for the treatment of protein misfolding diseases. The firm engages in the development of new chemical series for the treatment of non-orphan diseases whose etiology also lies in the accumulation of misfolded proteins. The company was founded in September 2013 by Philippe Guedat and Pierre Miniou and is headquartered in Nantes, France. | - |
| Immanuel Thangaraj | M | 53 |
Exubrion Therapeutics , Inc.
Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | - |
| Julia Stephanus | F | 65 |
Exubrion Therapeutics , Inc.
Exubrion Therapeutics , Inc. Medical SpecialtiesHealth Technology Exubrion Therapeutics, Inc. develops electron therapeutic veterinary devices. The company is based in Buford, GA. The company was founded by Dennis F. Steadman. The CEO is Peter Selover. | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kenneth Rice | M | 70 | 14 years | |
| Mike M. Goldberg | M | 65 | 5 years | |
| Paul Sekhri | M | 66 | 8 years | |
| Marcio Souza | M | 45 | 6 years | |
| Susan M. Flint | F | 73 | - | |
| Anne Marie Conway | F | - |
Agilis Biotherapeutics LLC
 Agilis Biotherapeutics LLC BiotechnologyHealth Technology Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA. | 3 years |
| Anne-Marie de Groot | F | 43 | 7 years | |
| Aad de Winter | M | 71 | 12 years | |
| Thomas Tulip | M | 71 | 4 years | |
| Noel J. Cusack | M | - | - | |
| Jess Emery Jones | M | 45 | 2 years | |
| Carl J. Aschinger | M | 85 | 7 years | |
| John Barrie Ward | M | 86 | 14 years | |
| David C. Bupp | M | 75 | 23 years | |
| William L. S. Guinness | M | 84 | - | |
| Peter Frank Drake | M | - | 4 years | |
| Fred B. Miller | M | 85 | 9 years | |
| Keng Kiat Toh | M | 83 | 3 years | |
| Jeffrey G. Smith | M | - | - | |
| Jodi Cook | M | 56 | - | |
| Perry Karsen | M | 69 | 1 years | |
| Edward O'Mara | M | - | 4 years | |
| Megan Sniecinski | F | 43 | 5 years | |
| Gregory Robinson | M | 65 |
Agilis Biotherapeutics LLC
Agilis Biotherapeutics LLC BiotechnologyHealth Technology Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA. | 2 years |
| Joseph McIntosh | M | - | - | |
| Kirby I. Bland | M | 82 | 6 years | |
| Robert Friesen | M | 60 | - | |
| Cornelia B. Reininger | M | - | 3 years | |
| David Colborn | M | - | - | |
| James R. Weston | M | - | - | |
| Mark R. Hurtt | M | - | - | |
| Gary E. Frashier | M | 86 | 3 years | |
| Owen E. Johnson | M | 84 | 4 years | |
| Frank Bobe | M | 66 | 2 years | |
| Henry Brem | M | 71 | 3 years | |
| John J. Canepa | M | 68 |
Agilis Biotherapeutics LLC
Agilis Biotherapeutics LLC BiotechnologyHealth Technology Agilis Biotherapeutics LLC operates as a biotechnology company. It focuses on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options. The company was founded in 2013 and is headquartered in Cambridge, MA. | 1 years |
| Joseph Hernon | M | 64 | 9 years | |
| Damian Clarke-Bruce | M | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 41 | 59.42% |
| Netherlands | 19 | 27.54% |
| France | 5 | 7.25% |
| Germany | 3 | 4.35% |
| Singapore | 1 | 1.45% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark Pykett
- Personal Network
